Pyxis Oncology Inc’s recently made public that its CFO & COO Connealy Pamela Ann acquired Company’s shares for reported $0.17 million on Nov 26 ’24. In the deal valued at $1.96 per share,88,850 shares were bought. As a result of this transaction, Connealy Pamela Ann now holds 1,199,143 shares worth roughly $1.87 million.
William Blair downgraded its Pyxis Oncology Inc [PYXS] rating to a Mkt perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in early November with a ‘”an Overweight”‘ rating. Stifel began covering PYXS with “Buy” recommendation on August 08, 2024.
Price Performance Review of PYXS
On Monday, Pyxis Oncology Inc [NASDAQ:PYXS] saw its stock fall -1.89% to $1.56. Over the last five days, the stock has lost -7.69%. Pyxis Oncology Inc shares have fallen nearly -13.33% since the year began. Nevertheless, the stocks have fallen -12.85% over the past one year. While a 52-week high of $6.85 was reached on 02/27/24, a 52-week low of $1.49 was recorded on 12/19/24. SMA at 50 days reached $2.7964, while 200 days put it at $3.5867.
Levels Of Support And Resistance For PYXS Stock
The 24-hour chart illustrates a support level at 1.5195, which if violated will result in even more drops to 1.4790. On the upside, there is a resistance level at 1.6110. A further resistance level may holdings at 1.6620. The Relative Strength Index (RSI) on the 14-day chart is 32.80, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0200, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.27%. Stochastics %K at 31.14% indicates the stock is a holding.
How much short interest is there in Pyxis Oncology Inc?
A steep rise in short interest was recorded in Pyxis Oncology Inc stocks on 2024-12-13, growing by 0.56 million shares to a total of 6.4 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 5.84 million shares. There was a rise of 8.73%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 09, 2024 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
